Celyad Oncology SA (CYAD.BR)
EUR 0.54
(-6.9%)
EUR 0.54
(-6.9%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.33 EUR | 81.77% |
| 2022 | -1.81 EUR | -6.47% |
| 2021 | -1.70 EUR | -34.92% |
| 2020 | -1.26 EUR | 44.98% |
| 2019 | -2.29 EUR | 29.75% |
| 2018 | -3.26 EUR | 44.37% |
| 2017 | -5.86 EUR | -131.62% |
| 2016 | -2.53 EUR | 26.24% |
| 2015 | -3.43 EUR | -40.57% |
| 2014 | -2.44 EUR | 18.94% |
| 2013 | -3.01 EUR | -785.29% |
| 2012 | -0.53 EUR | 76.39% |
| 2011 | -1.44 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.12 EUR | 0.0% |
| 2023 FY | - EUR | 81.77% |
| 2023 Q4 | -0.16 EUR | 0.0% |
| 2023 Q2 | -0.17 EUR | 0.0% |
| 2022 FY | - EUR | -6.47% |
| 2022 Q4 | -1.19 EUR | 0.0% |
| 2022 Q2 | -0.29 EUR | 14.71% |
| 2022 Q1 | -0.34 EUR | -142.86% |
| 2021 Q2 | -0.43 EUR | 29.51% |
| 2021 Q4 | -0.14 EUR | 39.13% |
| 2021 FY | - EUR | -34.92% |
| 2021 Q1 | -0.61 EUR | -274.29% |
| 2021 Q3 | -0.23 EUR | 46.51% |
| 2020 FY | - EUR | 44.98% |
| 2020 Q3 | -0.39 EUR | 67.23% |
| 2020 Q4 | 0.35 EUR | 189.74% |
| 2020 Q2 | -1.19 EUR | 0.0% |
| 2019 Q2 | -1.34 EUR | -135.09% |
| 2019 FY | - EUR | 29.75% |
| 2019 Q4 | -0.95 EUR | 0.0% |
| 2019 Q1 | -0.57 EUR | 64.15% |
| 2018 Q2 | -1.79 EUR | -113.1% |
| 2018 Q1 | -0.84 EUR | 80.47% |
| 2018 FY | - EUR | 44.37% |
| 2018 Q4 | -1.59 EUR | 0.0% |
| 2017 Q2 | -1.52 EUR | -3.4% |
| 2017 FY | - EUR | -131.62% |
| 2017 Q4 | -4.30 EUR | 0.0% |
| 2017 Q1 | -1.47 EUR | -104.17% |
| 2016 Q4 | -0.72 EUR | 0.0% |
| 2016 FY | - EUR | 26.24% |
| 2016 Q2 | -1.82 EUR | -188.89% |
| 2016 Q1 | -0.63 EUR | 55.94% |
| 2015 Q4 | -1.43 EUR | -66.28% |
| 2015 FY | - EUR | -40.57% |
| 2015 Q3 | -0.86 EUR | 59.05% |
| 2015 Q2 | -2.10 EUR | -144.19% |
| 2015 Q1 | -0.86 EUR | 39.44% |
| 2014 Q1 | -0.61 EUR | 51.97% |
| 2014 FY | - EUR | 18.94% |
| 2014 Q4 | -1.42 EUR | -132.79% |
| 2014 Q3 | -0.61 EUR | 38.38% |
| 2014 Q2 | -0.99 EUR | -62.3% |
| 2013 Q3 | -0.78 EUR | 77.26% |
| 2013 Q4 | -1.27 EUR | -62.82% |
| 2013 FY | - EUR | -785.29% |
| 2013 Q1 | -0.78 EUR | 0.0% |
| 2013 Q2 | -3.43 EUR | -339.74% |
| 2012 Q2 | -0.08 EUR | 0.0% |
| 2012 FY | - EUR | 76.39% |
| 2012 Q1 | -0.08 EUR | 0.0% |
| 2012 Q3 | -0.08 EUR | 0.0% |
| 2012 Q4 | -0.78 EUR | -817.65% |
| 2011 Q4 | -0.08 EUR | 76.39% |
| 2011 Q1 | -0.36 EUR | 0.0% |
| 2011 Q2 | -0.36 EUR | 0.0% |
| 2011 Q3 | -0.36 EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2010 Q4 | -0.36 EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Nicox S.A. | -0.42 EUR | 21.429% |
| European Medical Solutions | -0.00 EUR | -65900.0% |
| FERMENTALG | -0.32 EUR | -3.125% |
| argenx SE | -4.67 EUR | 92.934% |
| BioSenic S.A. | -0.21 EUR | -57.143% |
| Hyloris Pharmaceuticals SA | -0.55 EUR | 40.0% |
| Onward Medical N.V. | -1.20 EUR | 72.5% |
| Oxurion NV | -0.01 EUR | -2769.565% |
| PHAXIAM Therapeutics S.A. | -5.00 EUR | 93.4% |
| Financière de Tubize SA | 1.98 EUR | 116.667% |
| UCB SA | 1.81 EUR | 118.232% |